SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel therapeutics using its unique AI-driven discovery platform, today announced the closing of an ...

Support comes from new and existing investors, including life science, technology, growth, and sovereign wealth investors Financing closely follows announcements of Iambic’s clinical data for IAM1363 ...

Busy Iambic Therapeutics has picked up more than $100 million in new funding as it looks to advance its portfolio of AI-discovered therapeutics. The oversubscribed funding round comes on the heels of ...

Iambic Therapeutics welcomed former Recursion CFO Michael Secora to its C-suite on Monday morning. Secora now becomes the chief corporate development officer and CFO at Iambic, a San Diego-based ...

Iambic Therapeutics has advanced its first pipeline candidate into the clinic, an AI-designed treatment for human epidermal growth factor receptor 2 (HER2)-driven cancers that moved from discovery to ...

Drug discovery isn’t only about finding new targets. There’s still plenty of opportunity to find better ways to hit targets that are already drugged, according to Tom Miller, CEO of startup Iambic ...

SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage biotechnology company developing novel medicines using its AI-driven discovery and development platform, announced that Michael Secora ...

Revolution Medicines has zeroed in on Iambic Therapeutics’ AI drug discovery platform, striking a multi-year technology and research collaboration that gives Iambic the chance to earn up to $25 ...

IAM1363 shown to be active across both HER2-wild-type and HER2-mutated cancers, and in multiple disease indications; responses seen in patients previously treated with T-DXd and tucatinib IAM1363 ...

When most people think about a telegraph key, a piece of 1890s tech with a lever that moves up and down comes to mind. These ‘straight keys’ were terrible for telegraphers and led to repetitive stress ...